

## **West Virginia Medicaid Drug Utilization Review Board Minutes November 15, 2023**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

### **Members:**

Christopher Terpening, PharmD, PhD, Chair  
David Gloss, MD, Vice Chair  
Chris Booth, PharmD  
Michael Ballow, PharmD  
Scott Brown, RPh  
Kate Forman, PharmD  
Phillip Galapon, MD  
Lester Labus, MD  
Michael Lonsinger, PharmD  
Ernest Miller, DO  
Mary Nemeth-Pyles, MSN, RN, CS  
C.K. Babcock, PharmD

### **Members Absent:**

### **DHHR/BMS Staff:**

Lori Moles, PharmD  
Priya Shah, PharmD, Drug Utilization Review Coordinator  
Doug Sorvig, Data Analyst

### **Contract Staff:**

Jeffrey Barkin, MD – Change Healthcare  
Joe Bergondo, PharmD – Change Healthcare  
Eric Sears, RPh, Gainwell  
Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)  
Cory Chambliss, Acentra  
Scott Donald, PharmD, Acentra  
Alena Mitchell PharmD, Acentra

#### **1. INTRODUCTIONS**

- a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:02 pm EST. The DUR Board and others introduced themselves.

#### **2. APPROVAL OF MINUTES FROM September 20<sup>th</sup>, 2023 DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion.

#### **3. OLD BUSINESS**

- a. None

4. **NEW BUSINESS**

- a. **Speakers**
  - i. None
- b. **Updates from September 20<sup>th</sup>, 2023 P&T Committee Meeting**
  - i. Dr. Joe Bergondo presented the PDL status updates from the September 20<sup>th</sup>, 2023 P&T meeting.
- c. **Prior Authorization Criteria.** Attachment A
  - i. **PCKS9 inhibitors:** approved as amended – addition of Leqvio to the criteria.
  - ii. **Vraylar:** approved as presented.
  - iii. **Tezspire:** approved as presented.
  - iv. **Ingrezza:** approved as presented.
  - v. **Antiemetics – combination products:** approved as presented.
  - vi. **Zavspret:** approved as presented.
  - vii. **Norvir powder pack:** approved as presented.
  - viii. **Inpefa:** approved as presented.
  - ix. **Linzess:** approved as presented.
  - x. **Sunosi:** approved as presented.

5. **REPORTS – 3<sup>rd</sup> Quarter of 2023**

- a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2023 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the Third Quarter of 2023. Attachment C
- c. **Acentra Health:** Dr. Alena Mitchell presented a summary of the RDUR interventions for the Third Quarter of 2023. Attachment D

6. **OTHER BUSINESS**

- a. None

7. **NEXT MEETING AND ADJOURNMENT**

- a. The meeting concluded at 5:12 pm EST.
- b. The next meeting will be February 14<sup>th</sup>, 2024, from 4-6pm (EST) on a virtual platform.